Preclinical development of kinetin as a safe error-prone SARS-CoV-2 antiviral able to attenuate virus-induced inflammation.
Souza TML, Pinho VD, Setim CF, Sacramento CQ, Marcon R, Fintelman-Rodrigues N, Chaves OA, Heller M, Temerozo JR, Ferreira AC, Mattos M, Momo PB, Dias SSG, Gesto JSM, Pereira-Dutra F, Viola JPB, Queiroz-Junior CM, Guimarães LC, Chaves IM, Guimarães PPG, Costa VV, Teixeira MM, Bou-Habib DC, Bozza PT, Aguillón AR, Siqueira-Junior J, Macedo-Junior S, Andrade EL, Fadanni GP, Tolouei SEL, Potrich FB, Santos AA, Marques NF, Calixto JB, Rabi JA.
Souza TML, et al. Among authors: guimaraes ppg, guimaraes lc.
Nat Commun. 2023 Jan 13;14(1):199. doi: 10.1038/s41467-023-35928-z.
Nat Commun. 2023.
PMID: 36639383
Free PMC article.